Tag: Centre for Probe Development and Commercialization

OICR-supported cancer therapeutics company Fusion Pharmaceuticals acquired by AstraZeneca for up to US $2.4 billion

March 25, 2024

New CPDC spinout company aims to become global leader in developing and distributing radiopharmaceuticals

September 14, 2022

Ontario centre attracts national attention for probe research, development and commercialization

August 2, 2018

FACIT Portfolio Company Fusion Pharmaceuticals Closes US$46M Oversubscribed Series A

October 4, 2017

FACIT-Seeded Fusion Pharmaceuticals Closes US$25M Series A Led by Johnson & Johnson Innovation

February 23, 2017

From our Annual Report: Investing in the cure and the economy

October 5, 2016

FACIT invests in new CPDC spin-out company to aid development of potent radiotherapeutic

March 16, 2016

FACIT Announces Investment in Fusion Pharmaceuticals and Alpha-Emitting Radiotherapeutics

December 16, 2015